Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known
as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent …

Background—Peripheral percutaneous transluminal angioplasty is fraught with a substantial
risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating …

Background The best way to manage restenosis in patients who have previously received a
drug-eluting stent is unknown. We investigated the efficacy of paclitaxel-eluting balloons …

Objectives: The aim of this study was to evaluate the angiographic efficacy and clinical
outcomes of the Restore paclitaxel-coated balloon in a randomized trial designed to enable …

The prevalence of peripheral arterial disease (PAD) is increasing worldwide, with recent
global estimates exceeding 200 million people. Advanced PAD leads to a decline in …

Drug-coated balloon (DCB) technology was developed to deliver the antiproliferative drugs
to the vessel wall without leaving any permanent prosthesis or durable polymers. The …

Background—The purpose of this study was to investigate the elimination of paclitaxel from
the arterial wall after a single short administration with a coated balloon. Methods and …

Background—In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB)
therapy improved angiographic outcomes as compared with uncoated balloon (UCB) …

The process of restenosis is based on the interplay of various mechanical and biological
processes triggered by angioplasty-induced vascular trauma. Early arterial recoil, negative …